Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
Starting soon · Not applicable
Conditions studied: Diabete Mellitus
In brief
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.
Key facts
- Study ID
- NCT07589387
- Run by
- Washington University School of Medicine
- People needed
- 2800
- Starts
- 2026-05-01
- Expected to finish
- 2030-01-31
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aim 3 Inclusion Criteria:
- Patients will be screened for diabetes with symptoms of hyperglycemia or BMI >25 kg/m2 and over the age of 18 years old. Upon first or previous diagnosis, diabetes patients will be registered.
- Adults (≥18 years),
- Patients with previous diabetes diagnosis
- Patients with persistently elevated random glucose >200 mg/dl, fasting glucose >126 mg/dl, or hemoglobin A1c >6.5% on two or more occasions (when available)
- Patients taking glucose lowering medications
- Pregnant women are eligible for this program, or
- Cognitively impaired adults are eligible for this program.
You may not qualify if…
- - This program will not include any of the following special populations:
- Individuals who are not yet adults (minors): i.e. infants, children, or teenagers <18 years old, or
- Prisoners or other detained individuals.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.